Slu PP 915 Capsuels

Selective ERR (Estrogen-Related Receptor) Agonism

Target Receptor: SLU-PP-915 functions as a highly selective, full agonist of Estrogen-Related Receptors (ERRs, including ERRα, ERRβ, and ERRγ).

Distinction from Estrogen Receptors: Despite their naming, ERRs are orphan receptors in the nuclear receptor superfamily. They do not bind to estrogen nor induce estrogenic side effects on the reproductive system; instead, they serve as master regulators of mitochondrial function and cellular energy metabolism.

Activation of the PGC-1α / ERR Axis

Mitochondrial Biogenesis: Activating ERRs upregulates downstream gene expression profiles governing oxidative phosphorylation (OXPHOS), fatty acid β-oxidation (FAO), and the tricarboxylic acid (TCA) cycle.

Muscle Fiber Type Switching: Promotes the transformation of skeletal muscle fibers from fatigable "fast-twitch/Type II" to endurance-oriented, mitochondria-rich "slow-twitch/oxidative/Type I" fibers, mimicking high-intensity aerobic exercise responses at the cellular level without requiring physical exertion.

Estrogen-related receptor (ERR) signaling contributes to how skeletal muscle adapts to aerobic exercise, making SLU-PP-915 a research tool for studying exercise-associated molecular responses. In a mouse study, SLU-PP-915 increased running distance and duration under the tested conditions. Researchers also observed changes in **Ddit4** and mitochondrial-related gene expression and examined its effects alongside exercise training. These are **preclinical findings**; they do not establish that SLU-PP-915 capsules improve human endurance or replace exercise.

Researchers have used SLU-PP-915 to investigate the relationship between ERR activation, cardiac fatty acid metabolism, and mitochondrial function in a **mouse model of pressure overload-induced heart failure**. The study reported improvements in measures of cardiac function, fibrosis, and survival. These findings help researchers examine the role of energy metabolism in the heart, but they do not demonstrate a treatment effect in humans.

SLU-PP-915 is also relevant to **in vitro metabolism and analytical method development**. A 2026 study characterized the parent compound using LC-HRMS/MS and investigated its transformation in human liver microsomes and liver S9 fractions. Researchers identified **seven Phase I metabolites** in these in vitro systems and further confirmed three through chemical synthesis and NMR. The use of human liver-derived laboratory materials does **not** mean that human metabolism has been established in a clinical study. This work also highlights the need to distinguish SLU-PP-915 analytically from SLU-PP-332.

Metabolic Regulation & Anti-Obesity Effects

Increased Resting Energy Expenditure: Directly accelerates fatty acid oxidation by enhancing thermogenesis in brown adipose tissue (BAT) and driving browning in white adipose tissue (WAT).

Improved Insulin Sensitivity: Reduces ectopic lipid accumulation in liver and skeletal muscle tissues, significantly mitigating high-fat diet-induced glucose intolerance and insulin resistance.

Endurance Enhancement & Muscle Health

Sustained Energy Supply: Enhances fat utilization during prolonged exertion to spare muscle glycogen, substantially extending time-to-exhaustion in performance models.

Anti-Muscle Atrophy: Maintains muscle mass and mitochondrial density under conditions of aging, prolonged bed rest, or immobilization, demonstrating strong therapeutic potential against sarcopenia.

Cardiovascular & Metabolic Protection

Improves serum lipid profiles by lowering triglycerides and LDL levels, reduces the severity of non-alcoholic fatty liver disease (NAFLD/MASH), and exerts cardioprotective effects against obesity-induced cardiac remodeling.